Prolonged exercise after diuretic-induced hypohydration: effects on substrate turnover and oxidation.
To determine the influence of a diuretic-induced reduction in plasma volume (PV) on substrate turnover and oxidation, 10 healthy young males were studied during 60 min of cycling exercise at 61% peak oxygen uptake on two separate occasions > or =1 wk apart. Exercise was performed under control conditions (CON; placebo), and after 4 days of diuretic administration (DIU; Novotriamazide; 100 mg triamterene and 50 mg hydrochlorothiazide). DIU resulted in a calculated reduction of PV by 14.6 +/- 3.3% (P < 0.05). Rates of glucose appearance (R(a)) and disappearance (R(d)) and glycerol R(a) were determined by using primed constant infusions of [6,6-(2)H]glucose and [(2)H(5)]glycerol, respectively. No differences in oxygen uptake during exercise were observed between trials. Main effects for condition (P < 0.05) were observed for plasma glucose and glycerol, such that the values observed for DIU were higher than for CON. No differences were observed in plasma lactate and serum free fatty acid concentrations either at rest or during exercise. Hypohydration led to lower (P < 0.05) glucose R(a) and R(d) at rest and at 15 and 30 min of exercise, but by 60 min, the effects were reversed (P < 0. 05). Hypohydration had no effect on rates of whole body lipolysis or total carbohydrate or fat oxidation. A main effect for condition (P < 0.05) was observed for plasma glucagon concentrations such that larger values were observed for DIU than for CON. A similar decline in plasma insulin occurred with exercise in both conditions. These results indicate that diuretic-induced reductions in PV decreases glucose kinetics during moderate-intensity dynamic exercise in the absence of changes in total carbohydrate and fat oxidation. The specific effect on glucose kinetics depends on the duration of the exercise.
Roy
B D
BD
Department of Kinesiology, University of Waterloo, Waterloo, Ontario, Canada N2L 3G1.
Green
H J
HJ
Burnett
M
M
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D003681:Dehydration / Q000139:chemically induced / Q000378:metabolism* / Q000503:physiopathology; D003903:Deuterium; D004040:Dietary Carbohydrates / Q000493:pharmacokinetics; D004041:Dietary Fats / Q000493:pharmacokinetics; D004232:Diuretics / Q000008:administration & dosage; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005934:Glucagon / Q000097:blood; D005947:Glucose / Q000493:pharmacokinetics; D005990:Glycerol / Q000097:blood / Q000493:pharmacokinetics; D006801:Humans; D006852:Hydrochlorothiazide / Q000494:pharmacology; D007328:Insulin / Q000097:blood; D019344:Lactic Acid / Q000097:blood; D008099:Liver / Q000378:metabolism*; D008297:Male; D018482:Muscle, Skeletal / Q000378:metabolism*; D010101:Oxygen Consumption / Q000502:physiology; D005082:Physical Exertion / Q000502:physiology*; D010953:Plasma Volume / Q000187:drug effects / Q000502:physiology*; D049993:Sodium Chloride Symporter Inhibitors / Q000494:pharmacology; D014223:Triamterene / Q000008:administration & dosage
D001786:Blood Glucose; D004040:Dietary Carbohydrates; D004041:Dietary Fats; D004232:Diuretics; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D049993:Sodium Chloride Symporter Inhibitors; D006852:Hydrochlorothiazide; D019344:Lactic Acid; D005934:Glucagon; D003903:Deuterium; D005947:Glucose; D005990:Glycerol; D014223:Triamterene